Next Phase Newsletter

A venture capital firm was founded in 2012 and is based in San Diego, CA. The firm invests in a wide range of data-driven products that integrate AI, machine learning, and IoT. The firm is backed by a management team with a long, successful track record of building tech companies. The firm invests in the company’s early stages with an initial check size of $250 K with follow-on investments as the company matures, with equity and convertible loan as the preferred capital structures. The firm focuses on US-based companies, but may consider international companies with strongly innovative products that they can bring to the US market.

The firm will look at a range of verticals in the life sciences sector as long as there is a strong data-driven component in the company’s product. Sectors of interest include healthcare IT/digital health. The firm will not consider therapeutics or medical devices unless there is a heavy data component. The firm’s previous investments include an AI-driven image analysis platform for cancer detection, a computational DNA analysis platform for personalized cancer treatments, and a DNA amplification technology based on electric field-induced pH changes. The firm has their own AI Lab of top data scientists, so the company does not have to have the AI experts as long as they have the data, know how to get the data, and what information would be valuable to retrieve via machine learning applications.

The firm will work with companies backed by founders with deep domain expertise. The firm prefers deploying the venture studio model to help co-found companies, deploy their AI Lab experts, and will always take a board seat in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A private investment firm primarily invests in life sciences and disruptive technologies and is actively seeking new investment opportunities. The firm is most interested in USA-based companies, but is open to investing in other geographies given that the companies target the USA or EU markets.

The firm is most interested in therapeutics, and most of their portfolio companies have fallen in that sector thus far. The firm has reviewed medical device opportunities before, but has yet to make an investment in that space nor is that within the firm’s current focus. The firm steers away from digital health. Currently, the firm is most interested in vaccines, platform technologies, and reformulations and repurposed drugs (505(b)(2) or even ANDA regulatory pathway). For disease areas/indications, the firm is interested in infectious diseases, oncology/immuno-oncology, neurology, ophthalmology, and orphan diseases. The firm prefers to invest in clinical assets, and pre-IND assets are generally considered too early stage by the firm. For companies developing vaccines or in infectious diseases, the firm may consider earlier stage opportunities as the firm is most interested in these fields. The firm is also open to commercial stage opportunities.

The firm seeks to work with experienced management teams with a demonstrated track record of success. The firm generally co-invests alongside a syndicate and will not always seek a board seat. The firm does have strong strategic value-add, and seeks to work with their portfolio companies to help develop new R&D partnerships, commercial and licensing alliances, new drug development program collaborations, manufacturing, supply and distribution joint ventures, and more.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the US is expecting to close their first fund this year. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Europe, Israel, and Asia.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm with offices in USA and China has 2 business practices; managing a seed fund that invests exclusively in healthcare and life sciences, and an advisory business primarily for western biotech or life science companies that are looking to establish business opportunities and partnerships in greater China. The firm is starting to expand their network into the Middle East, especially Turkey. The firm is looking for Seed opportunities but is open to participation in Pre-Seed and Series A on a case by case basis. The typical check size is $50-250K in the form of equity or convertible notes. The firm will consider opportunities anywhere in the world.

The firm will look at all subsectors and indications but is not investing in immunotherapy or cancer at this time. The firm is particularly interested in chronic disease, especially diabetes and is starting to look at neurodegenerative diseases as well.  The firm is not doing biotech deals, but they’ve done deals in Healthcare IT and the AI space. The firm is focusing on diagnostics and digital health at the moment.

The firm is open to all management teams but prefers teams with prior start-up experience. The firm is not looking to do small participations in big rounds and would prefer to do investments where their stake has a meaningful impact on the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a family office invests in all sectors of the life sciences, looking for companies that are 2-5 years from exit. The firm invests globally, although they have a preference for companies based in the UK and in Central/Eastern Europe. The firm invests from Seed-Series C, and generally will invest $1-5M per round.

The firm is both sector and indication agnostic, and is less focused on stage of development and more focused on time to exit, looking for companies with a strategy that will allow them to exit within 2-5 years after the investment.

The firm generally does not act as a lead investor. The firm does not generally take a board seat, and is usually a silent investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech early stage investment firm headquartered in Asia invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.